Patent directory · USPTO A61K / A61P
Patents matching “REGENERON PHARMACEUTICALS, INC.”
837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 11117970
Human antibodies to PD-L1
granted -
US 11117955
Anti-Zika virus antibodies and methods of use
granted -
US 11116839
Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
granted -
US 11103552
High concentration VEGF receptor fusion protein containing formulations
granted -
US 11104730
Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
granted -
US 11104729
Anti-IL-33 antibodies and uses thereof
granted -
US 11104715
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
granted -
US 11102961
Non-human animals having a humanized lymphocyte-activation gene 3
granted -
US 11098311
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11098127
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
granted -
US 11098112
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11084865
VEGF antagonist formulations suitable for intravitreal administration
granted -
US 11072656
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
granted -
US 11071780
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
granted -
US 11066474
Anti-TrkB monoclonal antibodies and methods of use
granted -
US 11064685
Non-human animal models of retinoschisis
granted -
US 11066458
VEGF antagonist formulations suitable for intravitreal administration
granted -
US 11059896
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
granted -
US 11053309
Methods for treating active eosinophilic esophagitis
granted -
US 11053280
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11051499
Genetically modified mice and engraftment
granted -
US 11045522
Glucagon-like peptide 1 receptor agonists and uses thereof
granted -
US 11034768
Methods for treating or preventing asthma by administering an IL-4R antagonist
granted -
US 11026997
Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
granted